Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Sanofi's new heart deal

Posted 4 May 2021 PM

Sanofi has struck a deal with California-based medical genetics company Invitae to speed up diagnosis for patients suspected of having certain heart conditions by sponsoring its genetic testing programs at no-charge for Aussies. 

Invitae's Detect Cardiomyopathy and Arrhythmia program and Detect Muscular Dystrophy program marks the nation's first no-charge genetic test for patients suspected by their clinician of having a genetic cause for their cardiac or neuromuscular signs and symptoms.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Pharma face-slapped for success
Reputation is finding itself under threat again
Approvals Action
Low dose Symdeko ticked
Along with one generic drug
Special Report
March 2021 PBAC outcomes
Less than a quarter of major new listing requests recommended